Tirzepatide Weight Loss for MRD+ Early Breast Cancer
NCT06517212
Recruiting
This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating tumor DNA (ctDNA) and freedom from the development of metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas
Conditions: Breast Cancer, Breast Neoplasms, Breast Cancers
Register for Updates
Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide
NCT06657209
Not Yet Recruiting
This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD) and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provi... Read More
Gender:
ALL
Ages:
Between 30 years and 70 years
Trial Updated:
10/22/2024
Locations: Stanford University, Clinical and Translational Research Unit (CTRU), Stanford, California
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
NCT05708859
Recruiting
A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
10/10/2024
Locations: Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance, California
Conditions: Type II Diabetes, Atherosclerosis
Register for Updates
A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
NCT05810597
Completed
The main purpose of this study is to look at the amount of the study drug, tirzepatide, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of tirzepatide and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 14 weeks, including screening.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/17/2024
Locations: Qps-Mra, Llc, South Miami, Florida +2 locations
Conditions: Healthy
Register for Updates
Role Of Metabolic Adaptation In Weight Regain
NCT05766358
Completed
In a previous study (NCT04081337), 55 participants with obesity participated on a 18-week lifestyle intervention to reduce their body weight, targeting 10% body weight loss. The participants received tirzepatide (15mg after titration) or placebo during the weight loss intervention. Before and after the lifestyle intervention, energy expenditure (48-h room indirect calorimetry) and body weight and composition (dual-X-ray absorptiometry) were measured, thus enabling the assessment of metabolic ada... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Weight Loss, Weight Gain, Obesity
Register for Updates
A Study of Tirzepatide in Overweight and Very Overweight Participants
NCT04311411
Completed
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight. The study will also use imaging to learn more about how tirzepatide affects specific parts of the brain. The effect of tirzepatide on appetite will also be studied. The study will last up to about four months and will include up to 14 visits to the study center.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/21/2024
Locations: Indiana University School of Medicine, Indianapolis, Indiana +2 locations
Conditions: Obesity, Overweight
Register for Updates
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
NCT04660643
Completed
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which participants either continued tirzepatide or switched to placebo. The study lasted about 2 years (25 visits).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Cahaba Research, Pelham, Alabama +69 locations
Conditions: Obesity, Overweight
Register for Updates
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
NCT04657016
Completed
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: National Research Institute - Huntington Park, Huntington Park, California +64 locations
Conditions: Obesity, Overweight
Register for Updates
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
NCT04657003
Completed
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: University of Alabama - Department of Nutrition Sciences, Birmingham, Alabama +74 locations
Conditions: Type 2 Diabetes, Overweight, Obesity
Register for Updates
A Study of Tirzepatide (LY3298176) in Healthy Participants
NCT03375463
Completed
This study has four parts. Each participant will enroll in one part. Part A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a powder formulation mixed with water and given subcutaneously (SC) (just under the skin). Part A will measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Part B: The purpose of Part B is to evaluate the safety and tolerability of tirzepatide intravenous (IV) formulation when ad... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/02/2024
Locations: Covance, Dallas, Texas
Conditions: Healthy
Register for Updates
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
NCT04537923
Completed
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or without metformin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2023
Locations: Syed Research Consultants Llc, Sheffield, Alabama +134 locations
Conditions: Type 2 Diabetes
Register for Updates
A Study of LY3457263 in Obese Participants
NCT05582096
Completed
The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants. The study will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the body to remove it in overweight or obese participants. The study will last up to approximately 11 weeks.
Gender:
ALL
Ages:
Between 20 years and 70 years
Trial Updated:
07/17/2023
Locations: LabCorp CRU, Inc., Daytona Beach, Florida
Conditions: Overweight, Obesity
Register for Updates